| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8212304 | International Journal of Radiation Oncology*Biology*Physics | 2017 | 8 Pages |
Abstract
Use of HFxn is increasing and is associated with improved survival over CFxn. Our findings support the broadened use of HFxn for patients with early-stage glottic cancer undergoing definitive radiation therapy.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
William A. MD, Diana PhD, Andy BS, David MD, Ryan M. MD, PhD, Sana D. MD, PhD,